Tryptophan for Mood and Serotonin

Tryptophan is the unique dietary precursor of serotonin, the master mood neurotransmitter. The rate-limiting enzyme for brain serotonin synthesis is tryptophan hydroxylase 2 (TPH2), distinct from its peripheral cousin TPH1. Substrate availability matters: the classic acute tryptophan depletion (ATD) paradigm developed by Delgado and colleagues in 1990 demonstrated that depleting plasma tryptophan with an amino-acid drink lacking tryptophan rapidly precipitates depressive relapse in patients who had previously recovered on SSRIs, providing the most direct human evidence for the serotonin hypothesis of depression. The flip side — that supplemental tryptophan or 5-HTP can ameliorate mood — is real but more modest, partly because tryptophan competes with the branched-chain amino acids (leucine, isoleucine, valine) for the blood-brain barrier LAT1 transporter, and partly because the kynurenine pathway captures ~95% of dietary tryptophan before any of it reaches the serotonin pool. This page walks through the TPH2 biology, the ATD experiment, the carbohydrate-insulin-BCAA-clearance trick that opens the BBB to tryptophan, and the practical comparison with SSRIs and with 5-HTP.

Table of Contents

1. TPH2 — The Brain's Rate-Limiting Enzyme for Serotonin
2. TPH1 vs TPH2 — Why the Gut and Brain Are Separate Systems
3. Crossing the Blood-Brain Barrier via LAT1
4. The Carbohydrate-Insulin-BCAA-Clearance Trick
5. The Acute Tryptophan Depletion (ATD) Paradigm
6. Delgado 1990 — Tryptophan Depletion Reverses SSRI Remission
7. Comparison with SSRIs
8. Comparison with 5-HTP
9. Practical Clinical Applications
10. Cautions and Serotonin Syndrome
11. Key Research Papers
12. Connections

TPH2 — The Brain's Rate-Limiting Enzyme for Serotonin

Tryptophan hydroxylase is the enzyme that takes L-tryptophan and adds a hydroxyl group to position 5 of its indole ring, yielding 5-hydroxytryptophan (5-HTP). It is the slowest step in the whole tryptophan-to-serotonin pipeline, making it the rate-limiting enzyme. Tryptophan hydroxylase requires three cofactors: tetrahydrobiopterin (BH4), molecular oxygen, and iron at the active site.

For decades, tryptophan hydroxylase was treated as a single enzyme. In 2003, Walther and colleagues at the Max Delbruck Center in Berlin reported the unexpected discovery that vertebrates have two distinct tryptophan hydroxylase genes: TPH1, expressed almost exclusively in peripheral tissues (gut enterochromaffin cells, pineal gland, skin), and TPH2, expressed almost exclusively in the brain's serotonergic neurons of the raphe nuclei. The two enzymes have similar catalytic mechanisms but distinct gene regulation, distinct subcellular localization, and distinct sensitivity to substrate availability.

The TPH2 discovery was a major event in mood-disorder neuroscience because it meant that brain serotonin and gut serotonin are biochemically independent. The enzyme that makes brain serotonin is a different protein than the enzyme that makes gut serotonin. This explains why peripheral measures of serotonin (platelet uptake, urinary 5-HIAA, gut motility) have proven so unreliable as proxies for brain serotonin status and why pharmacologic manipulation of one compartment does not automatically affect the other.

TPH2 is not normally saturated with substrate under typical dietary intake. The implication is that substrate availability matters for brain serotonin output. Other rate-limiting enzymes (such as DOPA decarboxylase in the dopamine pathway) are typically substrate-saturated under physiologic conditions, so providing more substrate does not raise output. TPH2 is the exception: provide more tryptophan to the brain, and you measurably raise serotonin synthesis. Conversely, deplete tryptophan, and serotonin synthesis falls within hours. This biochemical fact is the foundation of both dietary tryptophan augmentation strategies and the acute tryptophan depletion (ATD) experimental paradigm.

Back to Table of Contents

TPH1 vs TPH2 — Why the Gut and Brain Are Separate Systems

Approximately 95% of the body's serotonin is made by TPH1 in gut enterochromaffin cells. This peripheral serotonin does important things — it regulates gut motility (the basis of the 5-HT3-antagonist anti-emetic class), platelet aggregation (platelets store but do not synthesize serotonin), bone remodeling (peripheral serotonin inhibits osteoblast proliferation), and inflammatory responses. But peripheral serotonin does not cross the blood-brain barrier in physiologically relevant amounts. The BBB is impermeable to serotonin itself; it is permeable only to tryptophan, the precursor.

This is why measurements of serum or platelet serotonin do not predict mood. It is why selective serotonin reuptake inhibitors (SSRIs) work on mood by acting in the brain's serotonergic synapses (TPH2 territory) and do not need to alter gut serotonin (TPH1 territory) to do so. And it is why the older literature describing "serotonin levels" without specifying which compartment is being measured was often confused.

For dietary tryptophan supplementation, the implication is two-fold:

• Some of an oral tryptophan dose will be diverted to gut TPH1 and made into peripheral serotonin. This is the source of the occasional GI side effects (nausea, loose stools) of high-dose tryptophan or 5-HTP supplementation.
• The fraction of an oral dose that actually reaches the brain depends on plasma tryptophan dynamics, competition with other LNAAs at the BBB, and the kynurenine pathway capture in the liver. Roughly 1–3% of an oral tryptophan dose ends up as new brain serotonin in young healthy adults.

Back to Table of Contents

Crossing the Blood-Brain Barrier via LAT1

Tryptophan does not freely diffuse across the blood-brain barrier. It is transported by the large neutral amino acid transporter LAT1 (gene symbol SLC7A5), a heterodimer of SLC7A5 and CD98 (4F2hc). LAT1 is highly expressed on both the luminal and abluminal surfaces of brain capillary endothelial cells and on the membranes of neurons and glia.

LAT1 transports several large neutral amino acids that compete with one another for the same carrier:

• Tryptophan
• Tyrosine
• Phenylalanine
• Leucine
• Isoleucine
• Valine
• Methionine
• Histidine

The transporter operates as an obligate exchanger — it moves one amino acid in and one out. Total brain uptake of any individual large neutral amino acid is determined not by its plasma concentration in isolation, but by its ratio to the sum of competing amino acids. This is the Fernstrom-Wurtman tryptophan ratio (plasma tryptophan divided by the sum of plasma valine, leucine, isoleucine, tyrosine, and phenylalanine). If that ratio goes up, brain tryptophan uptake goes up. If it goes down — even if tryptophan itself is unchanged — brain uptake goes down.

This is the molecular basis for the counterintuitive observation that eating protein does not predictably raise brain tryptophan. Mixed-protein foods raise plasma tryptophan, but they raise the competing BCAAs more (because tryptophan is the least-abundant essential amino acid in most foods). The ratio goes down, and brain tryptophan uptake actually falls.

Back to Table of Contents

The Carbohydrate-Insulin-BCAA-Clearance Trick

Pure carbohydrate ingestion, by contrast, paradoxically raises the brain-tryptophan ratio. The mechanism involves insulin. Carbohydrate triggers insulin release. Insulin powerfully stimulates muscle uptake of the branched-chain amino acids (leucine, isoleucine, valine), which are major fuel substrates for skeletal muscle. The BCAAs leave the bloodstream rapidly under insulin's influence. Tryptophan, in contrast, is largely bound to plasma albumin (60–80% bound depending on conditions) and is not transported into muscle to nearly the same extent. So insulin preferentially clears the competitors while leaving tryptophan in plasma.

Within 30–90 minutes after a pure-carbohydrate meal, the Fernstrom-Wurtman ratio rises, brain tryptophan uptake rises, and brain serotonin synthesis rises. The phenomenon was originally demonstrated by Richard Wurtman and John Fernstrom at MIT in the early 1970s and has been replicated extensively. It is the biochemical explanation for several familiar observations:

• Postprandial sleepiness after carb-heavy meals — the rise in brain serotonin (and downstream pineal melatonin output) acutely is part of the cause. This, not turkey-specific tryptophan, is the real mechanism of the Thanksgiving turkey myth.
• Carbohydrate craving in seasonal affective disorder (SAD), premenstrual dysphoric disorder (PMDD), and atypical depression — these subgroups appear to be self-medicating low brain serotonin tone through preferred carbohydrate intake.
• The advice to take L-tryptophan supplements on an empty stomach or with a small carbohydrate, not with a protein meal — this maximizes the ratio and the effective brain delivery.
• The Atkins-era complaint of mood disturbance on strict low-carbohydrate diets — brain tryptophan and serotonin tone drop measurably on very-low-carb diets, especially in the first weeks.

The clinical implication for tryptophan supplementation is to time the dose strategically: take L-tryptophan 30–60 minutes before bed on an empty stomach with a small carbohydrate (a banana, half a slice of bread with honey, a small glass of orange juice) and avoid pairing it with protein for at least 90 minutes either side.

Back to Table of Contents

The Acute Tryptophan Depletion (ATD) Paradigm

The acute tryptophan depletion experiment is one of the most elegant pieces of human neuroscience and is the most direct evidence we have for a causal role of brain serotonin in mood regulation.

The protocol exploits the same LAT1 transporter competition described above, but in reverse. Subjects are given an amino-acid drink containing all of the large neutral amino acids except tryptophan. The high load of competing LNAAs has two effects:

1. It drives competing amino acids into muscle and tissue protein synthesis, raising their plasma concentrations dramatically.
2. The same protein synthesis pulls free tryptophan out of the plasma pool because tissue protein synthesis demands tryptophan along with all other amino acids. Plasma tryptophan can fall by 75–85% within 4–6 hours.

The combined effect collapses the Fernstrom-Wurtman ratio to near zero. Brain tryptophan uptake essentially stops. Brain serotonin synthesis halts within hours. By 5–7 hours after the drink, brain serotonin tone has dropped substantially, and the mood and cognitive consequences become measurable.

The procedure is reversible. A normal meal containing tryptophan within 24 hours restores plasma tryptophan and brain serotonin to baseline. ATD is therefore a temporary, controlled, recoverable experimental manipulation of one neurotransmitter system in awake humans — an extraordinarily powerful tool that the field has used since the late 1980s to test the serotonin hypothesis of mood disorders directly.

Back to Table of Contents

Delgado 1990 — Tryptophan Depletion Reverses SSRI Remission

The most consequential ATD experiment was reported by Pedro Delgado and colleagues at Yale in Archives of General Psychiatry in 1990. They studied 21 patients with major depressive disorder who had achieved remission on serotonergic antidepressants. The patients were given the ATD amino acid drink in a single-blind crossover design (each patient served as their own control with a balanced placebo amino-acid mixture containing tryptophan).

The result was dramatic: 14 of the 21 patients (67%) experienced a complete or partial relapse of depressive symptoms within hours of the tryptophan-depleting drink. Hamilton Depression Rating Scale scores rose substantially within the same day. The relapses were transient — symptoms resolved within 24 hours as plasma tryptophan recovered — but they were unmistakable. Patients who had been clinically well became transiently and unmistakably depressed by removing tryptophan from the substrate pool.

Subsequent ATD studies expanded the picture:

• The effect was much stronger in patients who had recovered on serotonergic antidepressants (SSRIs, TCAs with serotonergic action) than in patients who had recovered on noradrenergic antidepressants (desipramine). This was consistent with serotonin being the relevant active mechanism for the SSRI patients.
• The effect was modest or absent in never-depressed healthy controls, indicating that low brain serotonin tone is sufficient to precipitate depression in patients with the disorder's underlying biology but not enough to produce de novo depression in resilient individuals.
• The effect was strongest in patients with a family history of mood disorders and in patients with high pre-treatment depression severity, suggesting that serotonin-tone sensitivity is a stable trait marker.

The Delgado experiment did not prove the simple "serotonin deficiency causes depression" hypothesis. It did establish that serotonin tone is a causally necessary input to mood maintenance in vulnerable individuals. This is a weaker but more defensible claim and is the modern consensus view of the serotonin hypothesis.

Back to Table of Contents

Comparison with SSRIs

SSRIs (fluoxetine, sertraline, escitalopram, citalopram, paroxetine, fluvoxamine) block the serotonin reuptake transporter (SERT), raising synaptic serotonin concentrations by preventing presynaptic reuptake. They do not change serotonin synthesis or substrate availability. The therapeutic effect typically takes 3–6 weeks to emerge, attributed to downstream neuroplastic changes (BDNF upregulation, dendritic spine remodeling, hippocampal neurogenesis) rather than the immediate pharmacology.

Tryptophan supplementation, by contrast, raises substrate availability for new serotonin synthesis. The dose-response is shallow (because TPH2 and the kynurenine pathway both buffer the effect), the onset is more gradual, and the magnitude of effect in moderate-to-severe major depression is small in head-to-head comparisons with SSRIs. The 2002 Shaw Cochrane review found that 5-HTP and L-tryptophan had a small but measurable antidepressant effect in mild-to-moderate depression compared with placebo, but the studies were generally small and short and have not produced regulatory drug approval.

The reasonable clinical framing is:

• SSRIs are first-line for moderate-to-severe major depression. The evidence base is overwhelmingly larger and the effect size is larger.
• Tryptophan and 5-HTP have a role in mild depression, in subclinical mood disturbance, and as adjuncts, particularly for patients who decline pharmaceutical antidepressants or who have responded incompletely to other interventions.
• Tryptophan is not a substitute for SSRIs in severe depression with suicidality. Underdosed substrate augmentation can be dangerous in that setting because it may delay effective treatment.
• Combining tryptophan or 5-HTP with an SSRI requires explicit physician supervision because of serotonin syndrome risk. See Cautions below.

For more on the broader management of depression, see Depression. For anxiety see Anxiety.

Back to Table of Contents

Comparison with 5-HTP

5-HTP and L-tryptophan are both serotonin precursors, but they enter the pathway at different points and behave differently in practice:

• 5-HTP bypasses TPH2 — the rate-limiting enzyme is already past. This means 5-HTP can produce a faster and steeper rise in serotonin per milligram of dose. Typical effective dose is 50–300 mg compared to 500–2000 mg for L-tryptophan.
• 5-HTP is decarboxylated by AADC peripherally and centrally. AADC is not BBB-restricted (it is expressed throughout peripheral tissues including the gut wall, the liver, and the kidneys). This means a substantial fraction of an oral 5-HTP dose is converted to serotonin in the gut, never reaches the brain, and contributes to GI side effects (nausea, vomiting, loose stools at higher doses).
• 5-HTP does not get diverted into the kynurenine pathway — it is committed to the serotonin/melatonin branch once 5-hydroxylated. L-tryptophan, by contrast, gets diverted to kynurenine at the ~95% rate.
• 5-HTP is theoretically more likely to disturb the dopamine/serotonin balance if used long-term without concurrent dopamine precursor (tyrosine or DOPA) support. AADC handles both 5-HTP and L-DOPA. Flooding it with 5-HTP could shift the AADC pool toward serotonin production at the expense of dopamine production in some tissue compartments. This has been the theoretical concern that some naturopathic and functional-medicine practitioners cite for preferring L-tryptophan for chronic use.
• 5-HTP comes from Griffonia simplicifolia seed extract, not from bacterial fermentation. Quality varies by manufacturer; reputable products test for and remove plant-source contaminants.

Clinical preference among integrative practitioners has historically favored L-tryptophan for long-term mood support (gentler, more physiologic, broader metabolic contribution) and 5-HTP for short-term or acute interventions where rapid effect matters (acute mood drop, sleep onset crisis, time-limited PMDD).

Back to Table of Contents

Practical Clinical Applications

• Mild-to-moderate depression in adults declining SSRI therapy — L-tryptophan 1000–2000 mg/day divided between evening (sleep) and mid-day (mood) doses. Add vitamin B6 (10–25 mg pyridoxal-5-phosphate), magnesium 200–400 mg, and a B-complex to ensure cofactor availability for TPH2 and AADC.
• Premenstrual dysphoric disorder (PMDD) — L-tryptophan or 5-HTP dosed during the luteal phase has the strongest evidence in mild-to-moderate PMDD. Combine with vitamin B6 and consider calcium 1000 mg/day.
• Seasonal affective disorder (SAD) — L-tryptophan or 5-HTP can be used as augmentation to bright light therapy. Light therapy is the first-line intervention; supplementation is adjunctive.
• Carbohydrate craving and emotional eating — modest L-tryptophan dose (500–1000 mg) before potentially-triggering meals may reduce craving severity in some patients. Magnesium and chromium are reasonable cofactor additions for the metabolic component.
• Generalized anxiety with low mood — L-tryptophan can be used as an adjunct to evidence-based interventions (CBT, exercise, sleep optimization). Not a substitute for first-line treatment in moderate-to-severe anxiety.
• Mild postpartum mood disturbance — do not self-treat. Postpartum mood disorders require professional evaluation. Tryptophan and 5-HTP have been used in research settings but should not be self-administered in this window.

Cofactor support is critical and frequently overlooked. TPH2 requires BH4 (downstream of folate metabolism), iron, and molecular oxygen. AADC requires pyridoxal-5-phosphate (active vitamin B6). The downstream serotonin-to-melatonin conversion requires SAMe (methionine cycle), B12, and folate. Patients with anemia (iron-deficient or B12-deficient) or with MTHFR-related folate cycle inefficiency may not get full benefit from tryptophan supplementation until the cofactor backbone is addressed.

Back to Table of Contents

Cautions and Serotonin Syndrome

• Serotonin syndrome — the most consequential interaction. Combining L-tryptophan or 5-HTP with any serotonergic drug can cause serotonin syndrome: agitation, tachycardia, hypertension, hyperthermia, hyperreflexia, clonus, tremor, sweating, mydriasis, autonomic instability, and in severe cases seizures, rhabdomyolysis, DIC, and death. The classic precipitants are SSRIs, SNRIs, MAO inhibitors, triptans (migraine drugs), tramadol, meperidine, linezolid, methylene blue, dextromethorphan, lithium, and MDMA (ecstasy). Do not combine without explicit psychiatric or primary-care supervision.
• Children and adolescents — not first-line. Pediatric mood disorder evaluation should precede any supplementation. The FDA Black Box warning on SSRIs in adolescents reflects the special vulnerability of this age group to medication-related mood and behavioral changes; the same caution applies to substrate supplementation.
• Bipolar disorder — tryptophan and 5-HTP can theoretically precipitate hypomanic or manic episodes in patients with bipolar diathesis, just as SSRIs can. Avoid in unstable bipolar disorder.
• Pregnancy and lactation — insufficient safety data for isolated supplementation; obtain dietary tryptophan through normal varied protein intake.
• Carcinoid syndrome — avoid supplementation in known serotonin-secreting carcinoid tumors. The dietary precursor will be converted to additional serotonin and worsen flushing, diarrhea, and bronchospasm.
• 1989–1990 EMS history — patients who had documented eosinophilia-myalgia syndrome from the original Showa Denko L-tryptophan should not resume supplementation. The mechanism of original susceptibility is not fully understood. See the Sleep and Melatonin deep-dive for the full EMS history.
• Hepatic and renal impairment — tryptophan metabolism is heavily hepatic. Patients with cirrhosis or significant renal impairment may have altered metabolism and should be supplemented only with physician oversight.

Back to Table of Contents

Key Research Papers

1. Delgado PL et al. (1990). Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Archives of General Psychiatry 47:411–418. — PubMed
2. Walther DJ et al. (2003). Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299:76. — PubMed
3. Fernstrom JD, Wurtman RJ (1971). Brain serotonin content: physiological dependence on plasma tryptophan levels. Science 173:149–152. — PubMed
4. Fernstrom JD, Wurtman RJ (1972). Brain serotonin content: increase following ingestion of carbohydrate diet. Science 174:1023–1025. — PubMed
5. Young SN et al. (1985). Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 87:173–177. — PubMed
6. Booij L et al. (2003). Predictors of mood response to acute tryptophan depletion: a reanalysis. Neuropsychopharmacology 27:852–861. — PubMed
7. Shaw K et al. (2002). Tryptophan and 5-Hydroxytryptophan for depression. Cochrane Database of Systematic Reviews. — PubMed
8. Markus CR et al. (2000). The bovine protein alpha-lactalbumin increases the plasma ratio of tryptophan to the other large neutral amino acids, and in vulnerable subjects raises brain serotonin activity, reduces cortisol concentration, and improves mood under stress. American Journal of Clinical Nutrition. — PubMed
9. Halbreich U et al. (1989). Possible acceleration of age effects on cognition following menopause. Biological Psychiatry. — PubMed
10. Steinberg S et al. (1999). A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biological Psychiatry. — PubMed
11. Lam RW et al. (1996). L-tryptophan augmentation of light therapy in patients with seasonal affective disorder. Canadian Journal of Psychiatry. — PubMed
12. Boyer EW, Shannon M (2005). The serotonin syndrome. NEJM 352:1112–1120. — PubMed

PubMed Topic Searches

• PubMed: Tryptophan and depression clinical trials
• PubMed: Acute tryptophan depletion
• PubMed: TPH2 brain serotonin
• PubMed: LAT1 BBB amino acid transport
• PubMed: Serotonin syndrome

Back to Table of Contents

Connections

• Tryptophan Overview
• Tryptophan Benefits Hub
• Tryptophan for Sleep
• Tryptophan and Niacin
• Tryptophan and Cognition
• Depression
• Anxiety
• Insomnia
• Tyrosine (Dopamine Precursor, LNAA Competitor)
• Phenylalanine
• Leucine (BCAA Competitor)
• Isoleucine
• Valine
• Vitamin B6 (AADC Cofactor)
• Magnesium

Back to Table of Contents